In those studies, in fact, patient enrollment was skewed toward highly-selected individuals who were fit to IFN therapies, thereby excluding a majority of patients with more advanced liver disease who were IFN unable or intolerant, while notoriously being at high risk of developing HCC. Here, IFNA1 is linked to hepatocellular carcinoma.